Medical Information Only. Consult your healthcare provider before enrolling in any clinical trial.

ClinicalTrials.gov 2,710 recruiting now below national open share #5 of 52 states

Massachusetts: below-average open trial sites

2,710 of 7,667 in-state trials are recruiting (35%); below the 37% national average by 2 percentage points.

According to ClinicalTrials.gov-derived indexes, Massachusetts sits in the top decile of US states by in-state trial count (#5 of 52 states by registered in-state trial count).

Massachusetts: 7,667 US clinical trials with in-state sites, 2,710 recruiting.

Massachusetts has 7,667 registered US clinical trials with a study site in-state, 2,710 of them currently recruiting (below the 37% national average by 2 percentage points). 1,108 of these trials are in Phase 3 (late-stage) and 1,636 in Phase 2. The most frequently studied condition in Massachusetts is Breast Cancer, with 184 linked trials.

Peer research-density states

Massachusetts is in the top decile by in-state trial count. Nearest hubs by indexed volume (not open-share twins):

Ranked from 51 other states with active in-state trials by how close each state's indexed trial count sits to Massachusetts's.

Below-average open enrollment

Massachusetts still shows 2,710 recruiting of 7,667 in-state trials (35% open), but below the 37% national average by 2 percentage points, so archived statuses weigh heavier than the national baseline.

35%
open (below national share)
2,710
still recruiting despite cool share
1,636
Phase 2 rows in this footprint
184
top: Breast Cancer

Recruiting share is below the 37% national average by 2 percentage points. Counts include every study with at least one recorded site in the state. Registry reference only, not medical advice.

Massachusetts vs all states by indexed in-state trial count

Where this state's ClinicalTrials.gov site count sits among every state with at least one listed trial (coverage density, not care quality)

7,667 Top 10% more indexed trials than 90% of 52 states

States, banded by indexed in-state trial count

Each bar is a band; taller bars hold more states. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov · 2026-08-08

Key findings

What ClinicalTrials.gov does not surface for Massachusetts on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Massachusetts open-enrollment share matches the national baseline.

    2,710 of 7,667 in-state trials (35.3%) are recruiting, against 37% nationally (-1.7 percentage points). Counts include every study with at least one recorded site in the state.

  2. Boston dominates Massachusetts's trial geography.

    Boston lists 6,313 of 7,667 in-state trials (82.3%) across 1,385 named facilities. Cities need five or more listed trials to appear here; locations are as filed by sponsors.

  3. Breast Cancer is the most-studied condition in Massachusetts.

    184 of 7,667 in-state trials (2.4%) list Breast Cancer. That is a local concentration figure, not a national disease ranking.

  4. Massachusetts sponsorship is fragmented across many organizations.

    Massachusetts General Hospital appears on 730 of 7,667 in-state trials (9.5%). Sponsor identity is as filed on ClinicalTrials.gov.

  5. 3,189 Massachusetts trials carry a completed status.

    3,189 of 7,667 (41.6%) are completed. The open share above is the remainder that still lists recruiting.

NA2,082Phase 21,636Phase 11,272Phase 31,108Phase 4294Early Phase 172
Treemap Treemap of 15 categories, sized proportional to value. Breast Cancer 184 HIV Infections 142 Non-Small Cel… 98 Multiple Myel… 97 Prostate Ca… 91 Obesity 80 Ovarian Cancer 74 Depression 70 Heart Failu… 65 Colorectal … 64 Lung Cancer 62 Cancer 59 Asthma 57 Major Depressive Disorder 56 Acute Myeloid Leukemia 54

Where trials run in Massachusetts

Boston carries 6,313 of Massachusetts's 7,667 indexed trials (82%) across 1,385 named sites, ahead of Worcester at 432. 8 cities clear five listed trials, together naming 1,795 distinct sites.

City Trials Listed sites
Boston 6,313 1,385
Worcester 432 162
Springfield 149 54
Burlington 140 39
Cambridge 123 59
Charlestown 101 38
Belmont 75 19
Waltham 63 39

Distinct trials and named sites per city, as filed with ClinicalTrials.gov; cities under five trials omitted. Vintage 2026-08-08.

Volume high

Massachusetts indexes 7,667 in-state trials (p92 by registry volume among 52 states with sites).

Massachusetts: in-state trial volume sits in the high tercile

Geography is concentrated: Boston alone accounts for 82% of Massachusetts's indexed trials (6,313 of 7,667), with Worcester a distant second at 432.

Phase mix: 1,108 Phase 3 vs 1,636 Phase 2 (balanced across stages).

Top condition: Breast Cancer (184 trials); top sponsor Massachusetts General Hospital (730).

high-volume · high-open figures (7,667 trials · 35% open) describe registry geography under the volume high read, not clinic capacity or protocol fit. Confirm status on ClinicalTrials.gov before acting.

States near Massachusetts on in-state trial volume

Cross-state peers under the volume high read (high-volume · high-open), not the same-state browse list.

Similar high-volume hubs (± open share)

Similar high-open peers (± trial volume)

  • Wyoming · 35% recruiting · 17 trials
  • Ohio · 35% recruiting · 6,514 trials
  • New York · 35% recruiting · 10,554 trials
  • South Carolina · 35% recruiting · 1,706 trials
  • Minnesota · 36% recruiting · 4,506 trials
Source: ClinicalTrials.gov, the US trial registry maintained by the National Library of Medicine, part of the NIH. Massachusetts series (high-volume · high-open · volume high) retrieved and formatted by PlainTrial, see methodology.